Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLR1A | O95602 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182244 | 0.89 | KDM4E (0.37) | ACHESIGMAR1BCHETGFBR1RXFP1 | |
| SCHEMBL28197375 | 0.87 | KDM4E (0.36) | ACHESIGMAR1BCHETGFBR1MEN1 | |
| SCHEMBL13298011 | 0.86 | ACHE (0.44) | ACHESIGMAR1BCHEKDM5BMEN1 | |
| SCHEMBL12285680 | 0.85 | TGFBR1 (0.39) | TGFBR1RXFP1TSHR | |
| SCHEMBL4824499 | 0.80 | TGFBR1 (0.41) | TGFBR1RXFP1ALDH1A1TSHR | |
| SCHEMBL4460484 | 0.79 | CA12 (0.37) | ACHETGFBR1KMT2AALDH1A1TSHR | |
| SCHEMBL5258395 | 0.79 | KDM4E (0.46) | ACHESIGMAR1BCHEKDM5BMEN1 | |
| SCHEMBL28222772 | 0.79 | ACHE (0.36) | ACHESIGMAR1BCHEKDM5BALDH1A1 | |
| SCHEMBL18976875 | 0.78 | TGFBR1 (0.33) | TGFBR1RXFP1 | |
| SCHEMBL21499 | 0.78 | DNM1 (0.43) | MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107698755-B | Cationic polymer and preparation method and application thereof | 四川大学 | 2021-03-30 | — | — | CN | claimed |
| WO-2023096923-A1 | STIMULI RESPONSIVE BLOCK COPOLYMERS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230158148-A1 | STIMULI RESPONSIVE BLOCK COPOLYMERS | BOSTON SCIENTIFIC SCIMED INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210220258-A1 | ORAL DOSAGE FORM WITH SURFACE DELIVERY OF ACTIVE AGENT | ENTREGA INC. | 2021-07-22 | — | — | US | disclosed |
| CN-107698755-B | Cationic polymer and preparation method and application thereof | 四川大学 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020072729-A1 | ORAL DOSAGE FORM WITH SURFACE DELIVERY OF ACTIVE AGENT | ENTREGA INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-9879108-B2 | Composition, cured film, color filter, laminate, and pigment dispersant | FUJIFILM CORPORATION (JP) | 2018-01-30 | — | — | US | disclosed |
| US-20160075807-A1 | COMPOSITION, CURED FILM, COLOR FILTER, LAMINATE, AND PIGMENT DISPERSANT | FUJIFILM CORPORATION (JP) | 2016-03-17 | — | — | US | disclosed |
| US-7407706-B2 | Encapsulated matter comprising multiple polymeric coatings of opposite charges and production process thereof | SEIKO EPSON CORPORATION (JP) | 2008-08-05 | — | — | US | disclosed |
| US-20060222851-A1 | Encapsulated matter and production process thereof | SEIKO EPSON CORPORATION | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220258-A1 | ORAL DOSAGE FORM WITH SURFACE DELIVERY OF ACTIVE AGENT | SI, FABP2, SLC10A2 | ACHE 1975/4885SIGMAR1 616/4885BCHE 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.